162 related articles for article (PubMed ID: 27816107)
1. Carbohydrate-Processing Enzymes of the Lysosome: Diseases Caused by Misfolded Mutants and Sugar Mimetics as Correcting Pharmacological Chaperones.
Stütz AE; Wrodnigg TM
Adv Carbohydr Chem Biochem; 2016; 73():225-302. PubMed ID: 27816107
[TBL] [Abstract][Full Text] [Related]
2. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
Sánchez-Fernández EM; García Fernández JM; Mellet CO
Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
[TBL] [Abstract][Full Text] [Related]
3. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
[TBL] [Abstract][Full Text] [Related]
4. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
Thomas R; Kermode AR
Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases.
Marques ARA; Saftig P
J Cell Sci; 2019 Jan; 132(2):. PubMed ID: 30651381
[TBL] [Abstract][Full Text] [Related]
6. Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders.
Kuech EM; Brogden G; Naim HY
Biochimie; 2016 Nov; 130():152-162. PubMed ID: 27664461
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
Parenti G; Andria G; Valenzano KJ
Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
[TBL] [Abstract][Full Text] [Related]
8. pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases.
Mena-Barragán T; Narita A; Matias D; Tiscornia G; Nanba E; Ohno K; Suzuki Y; Higaki K; Garcia Fernández JM; Ortiz Mellet C
Angew Chem Int Ed Engl; 2015 Sep; 54(40):11696-700. PubMed ID: 26386364
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in therapeutic approaches for lysosomal storage diseases.
Urbanelli L; Magini A; Polchi A; Polidoro M; Emiliani C
Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432
[TBL] [Abstract][Full Text] [Related]
10. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.
Shayman JA; Larsen SD
J Lipid Res; 2014 Jul; 55(7):1215-25. PubMed ID: 24534703
[TBL] [Abstract][Full Text] [Related]
11. [Design of fluorogenic substrates of lysosomal hydrolases and their use in the study and diagnosis of hereditary enzyme defects].
Tsvetkova IV
Vestn Ross Akad Med Nauk; 1995; (2):52-6. PubMed ID: 7756932
[TBL] [Abstract][Full Text] [Related]
12. Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.
Naganawa Y; Itoh K; Shimmoto M; Kamei S; Takiguchi K; Doi H; Sakuraba H
Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):467-74. PubMed ID: 10333491
[TBL] [Abstract][Full Text] [Related]
13. A Glycoengineered Enzyme with Multiple Mannose-6-Phosphates Is Internalized into Diseased Cells to Restore Its Activity in Lysosomes.
Hyun JY; Kim S; Lee HS; Shin I
Cell Chem Biol; 2018 Oct; 25(10):1255-1267.e8. PubMed ID: 30146240
[TBL] [Abstract][Full Text] [Related]
14. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
Haneef SA; Doss CG
Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
[TBL] [Abstract][Full Text] [Related]
15. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction.
Platt FM; Boland B; van der Spoel AC
J Cell Biol; 2012 Nov; 199(5):723-34. PubMed ID: 23185029
[TBL] [Abstract][Full Text] [Related]
16. [Lysosomes and lysosomal storage diseases].
Germain DP
J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
Hou ZS; Ulloa-Aguirre A; Tao YX
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Ca2+ homeostasis in lysosomal storage diseases.
Kiselyov K; Muallem S
Cell Calcium; 2008 Jul; 44(1):103-11. PubMed ID: 18242695
[TBL] [Abstract][Full Text] [Related]
19. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones.
Wei H; Kim SJ; Zhang Z; Tsai PC; Wisniewski KE; Mukherjee AB
Hum Mol Genet; 2008 Feb; 17(4):469-77. PubMed ID: 17989065
[TBL] [Abstract][Full Text] [Related]
20. [Pathobiochemical aspects of lysosomal enzymes with special reference to lysosomal storage diseases (author's transl)].
Kresse H
Wien Klin Wochenschr; 1978 May; 90(10):325-32. PubMed ID: 418578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
